Through the development of proprietary molecules to treat diseases with inflammatory, fibrotic, and metabolic disease processes.

Skye’s first-in-class and only-in-class SBI-100 Ophthalmic Emulsion is focused on developing a treatment for glaucoma, the world’s leading cause of irreversible blindness.

Nimacimab is a first-in-class and only-in-class Phase II-ready, negative allosteric modulator antibody focused on CB1 inhibition and is being developed to potentially treat with fibrotic, inflammatory and metabolic-related diseases with significant prevalence and unmet need.